Authors |
Objective |
Study type |
Results |
Yafi et al. [14] |
Role of adjuvant chemotherapy in patients with UTUC treated by RNU |
retrospective |
OS: P = 0.8800 |
Necchi et al. [15] |
Analyse the outcomes of adjuvant chemotherapy vs observation |
Joint study |
OS (HR 1.25, 95% CI 1.02–1.54) |
Jazayeri et al.[21] |
Comparison of adjuvant chemotherapy for UTUC versus LTUC |
meta-analysis |
DFS (HR 0.61, 95%CI 0.1–0.93) |
Quhal et al.[16] |
Efficacy of neoadjuvant and adjuvant chemotherapy for UTUC |
meta-analysis |
MFS (HR 0.65, 95% CI 0.55–0.76, p<0.001) |
Leow JJ et al.[17] |
Role of neoadjuvant and adjuvant chemotherapy for UTUC patients. |
meta-analysis |
OS HR 0.43 (95% CI, 0.21–0.89; p = 0.023) |
Luo Y et al.[18] |
Outcomes of RNU combined with adjuvant chemotherapy in patients with high risk UTUC |
prospective |
PFS [P = 0.0033, HR = 3.78 (3.13–4.55)], |
Seisen et al.[19] |
Effectiveness of Adjuvant Chemotherapy After RNU for Locally Advanced and/or Positive Regional Lymph Node UTUC |
retrospective |
OS (HR, 0.77 [95% CI, 0.68 to 0.88]; P , .001) |
Birtle A et al.[23] |
Adjuvant chemotherapy in UTUC (the POUT trial) |
phase 3, open label, randomized controlled trial |
DFS (HR = 0·45, 95% CI 0·30–0·68; p=0·0001) |
Bellmunt et al.[3] |
Adjuvant atezolizumab high-risk muscle invasive urothelial carcinoma after RNU (IMvigor010) |
phase 3, open label, randomized controlled trial |
DFS HR = 1.25 (95% CI 0.57-2.74) |
Bajorin et al.[24] |
Adjuvant nivolumab high-risk muscle invasive urothelial carcinoma after RNU (CheckMate 274) |
phase 3, double-blind, randomized controlled trial |
For UTUC patients: DFS HR = 1.23 (CI 95% 0.67-2.23) |
CI: confidence interval, CSS: cancer-specific survival, DFS: Disease Free-Survival, HR: Hazard Ratio, LTUC: Lower Tract Urothelial Carcinoma, MFS: metastasis Free Survival, OS: Overall Survival, PFS: Progression Free Survival, RNU: Radical Nephroureterectomy, UTUC: Upper Tract Urothelial Carcinoma
Table 1: Summary of available studies on adjuvant therapy in UTUC patients
Tables at a glance